Kazia Therapeutics (NASDAQ:KZIA) Stock, Quote.Headers.trade-ideas

Kazia Therapeutics

Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing innovative anti-cancer drugs. The group is developing paxalisib, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others. The company is also developing EVT801 for the treatment of various tumors.

Image49

News

Intraday Update

Markets

Movers

Trading Ideas

AEON

AGRI

AMIX

AREB

ASLN

ASTL

COIN

DATS

EAST

FSLR

FUFU

HUMA

INOD

KZIA

LCFY

LCID

LXEO

MIRA

MLEC

MSTR

NAAS

NOVA

PETZ

POWW

Qualigen Therapeutics, Inc. - Common Stock

QLGN

SCNI

SEDG

SQNS

TSLA

UPST

VTAK

Why SolarEdge Shares Are Trading Lower By 12%? Here Are Other Stocks Moving In Monday&#39;s Mid-Day Session

Citibank

Earnings

Eurozone

Commodities

NISN

SISI

ZAPP

S&amp;P 500 Rises Over 1%; Citigroup Reports Upbeat Q2 Results

ACHR

ASPI

BDRX

BILI

CGBS

COCO

ERIC

EVGO

EYPT

FWRD

HOVR

IMMP

LIPO

PEGY

RNLX

SANW

SNTG

SXTC

TOYO

VALU

VRPX

VSTM

YGMZ

Why ASP Isotopes Shares Are Trading Lower By 9%? Here Are Other Stocks Moving In Friday&#39;s Mid-Day Session

Kazia Therapeutics Limited - American Depositary Shares

Kazia Therapeutics Ltd

Mark Cuban responded to posts criticizing Vice President Kamala Harris and defended her policies over those of former President Donald Trump over X.
What Happened: On Wednesday, X user Andy Swan accused Harris of wanting to confiscate equity from successful startups through an &#8220;unrealized capital gains tax&#8221; and promoting &#8220;equity&#8221; as everyone ending up in the same place. Swan also compared Harris unfavorably to Trump.
Cuban clarified that Harris never proposed an unrealized gains tax, attributing that to President Joe Biden instead. He pointed out that Trump has proposed price controls, a tariff tax on all imports, and punishing companies that produce in Mexico despite the USMCA agreement.
See Also: <a href="https://www.benzinga.com/news/24/09/40973072/lindsey-graham-says-either-saudi-arabia-recogonizes-israel-or-tel-aviv-targets-tehran-we-need-game-c?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Lindsey Graham Says Either Saudi Arabia Recogonizes Israel Or Tehran Gets Targeted: &#8216;We Need Game Changing Peace Or Game Changing Military Strategy&#8217; (UPDATED)</a>
In a follow-up exchange, Swan suggested that Cuban selectively supports Biden-Harris policies. 
Cuban countered, &#8220;Trump has a new tax cut or tariff for every city he visits. Even when it violates his own signed policies or the law.&#8221;
&#8220;I tell you what I know from my conversations. Her campaign actually thinks through proposals before she says them.&#8221;
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">You have that backwards. Trump has a new tax cut or tariff for every city he visits. Even when it violates his own signed policies or the law. I tell you what I know from my conversations. Her campaign actually thinks through proposals before she says them
&mdash; Mark Cuban (@mcuban) <a href="https://twitter.com/mcuban/status/1838695497386586171?ref_src=twsrc%5Etfw">September 24, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Why It Matters: Cuban&#8217;s defense of Harris comes <a href="https://www.benzinga.com/news/24/09/40933169/mark-cuban-teams-up-with-kamala-harris-to-protect-american-businesses-from-unfair-foreign-competitio">amid his ongoing support</a> for her pro-business stance. Recently, Cuban teamed up with Harris to protect American businesses from unfair foreign competition, particularly from Chinese knockoffs. He emphasized the detrimental impact of knockoffs on small businesses, stating they &#8220;cost them time, money and may put them out of business.&#8221; 
Cuban has praised Harris for <a href="https://www.benzinga.com/startups/24/09/40855223/mark-cuban-praises-kamala-harris-support-for-business-is-her-new-tax-plan-a-game-changer">listening to business leaders</a> and gathering feedback on fair policies that encourage investment in businesses. He described her as more supportive of entrepreneurs than any other candidate in recent memory. 
Additionally, Cuban has been vocal about his <a href="https://www.benzinga.com/startups/24/09/41008222/mark-cuban-wants-to-crack-down-on-chinese-knockoffs-says-vice-president-kamala-harris-is-on-board-wi">mission to crack down</a> on Chinese knockoffs, with Harris showing support for his plan. He highlighted the serious impact of counterfeit products on small businesses, likening it to an endless game of whack-a-mole. 
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/09/40993290/trump-vs-harris-2024-election-betting-odds-show-vice-president-maintains-lead-as-race-near?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Trump Vs. Harris: 2024 Election Betting Odds Show Vice President Maintains Lead As Race Nears One-Month Mark</a></li>
</ul>
Image via Shutterstock
This story was generated using <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a> and edited by <a href="https://www.benzinga.com/topic/Pooja-Rajkumari" target="_blank" rel="noreferrer noopener">Pooja Rajkumari</a>

Politics

General

Mark Cuban Fires Back At Criticism Of Kamala Harris Tax Policies: 'Trump Has A New Tax Cut Or Tariff For Every City He Visits'

Events

Bank Of America CFO Alastair Borthwick, Speaking At Financials CEO Conference, Said Consumer Spending Is Growing Albeit At A Slower Pace; Said Fed Seems To Be Winning The Inflation Battle

Meta Platforms, Inc. CEO Mark Zuckerberg has reportedly moved his political ideologies from activism to regret, leaning towards classic liberalism.
What Happened: Zuckerberg, once an enthusiastic activist, has grown cynical about politics due to his experiences in Washington and the political scrutiny faced by his company, <a href="https://www.nytimes.com/2024/09/24/technology/mark-zuckerberg-trump-politics.html">reported</a> The New York Times.
His early enthusiasm for topics like immigration and social justice has diminished due to negative experiences in Washington and backlash against Meta&#8217;s political involvement
The Meta CEO now prefers to avoid political discussions publicly, opting instead for a more neutral stance. Several instances led to this shift.
See Also:&nbsp;<a href="https://www.benzinga.com/news/24/09/40974511/iphone-15-pro-models-and-iphone-13-discontinued-by-apple-heres-why?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">iPhone 15 Pro Models and iPhone 13 Discontinued By Apple: Here&#8217;s Why</a>
For example. after the 2020 election, Zuckerberg faced backlash for donating $400 million to the Center for Tech and Civic Life for voting safety during pandemic lockdowns.
The donation was criticized as &#8220;Zuckerbucks&#8221; by former President Donald Trump, who alleged it aimed to boost Democratic voter turnout. According to the report, Zuckerberg has expressed regret over the fallout from their contributions.
Later in 2021, Zuckerberg and his wife, Dr. Priscilla Chan decided to halt the Chan Zuckerberg Initiative&#8217;s internal political efforts, opting to support two bipartisan organizations, including Fwd.us.
Privately, Zuckerberg now identifies more with libertarianism or &#8220;classical liberalism.&#8221; This includes a preference for free markets, globalism, and skepticism of regulations that restrict businesses, the report noted, citing people who have spoken to him.
Subscribe to the&nbsp;<a href="https://bztechtrends.beehiiv.com/subscribe" target="_blank" rel="noreferrer noopener">Benzinga Tech Trends newsletter</a>&nbsp;to get all the latest tech developments delivered to your inbox.
Difference Between Musk And Zuckerberg&#8217;s Political Evolution
While Zuckerberg has grown cynical about politics, Elon Musk has embraced a provocative and openly conservative approach, particularly after acquiring X, formerly Twitter, where he champions free speech principles. The Tesla CEO has also <a href="https://www.benzinga.com/markets/equities/24/07/39815808/elon-musk-claps-back-after-gavin-newsom-shares-donald-trumps-drop-to-your-knees-and-beg-post-abo">publicly supported Trump</a> for the 2024 U.S. presidential election.
Why It Matters: Earlier this month in an interview, Zuckerberg said that he has <a href="https://www.benzinga.com/news/24/09/40866457/mark-zuckerberg-says-he-is-done-apologizing-reveals-one-of-the-biggest-mistakes-of-his-career">grown tired of taking on too</a> much ownership of problems beyond his or his company&#8217;s control.
Previously, he had also revealed that the Joe Biden administration pressured Meta to censor certain COVID-19 content. The tech mogul expressed <a href="https://www.benzinga.com/general/biotech/24/08/40575260/mark-zuckerberg-reveals-biden-administration-pressured-meta-platforms-to-censor-certain-covid-19-">regret for not opposing</a> the pressure sooner.
His relationship with former President Trump has also been contentious. 
Trump has criticized Zuckerberg in his <a href="https://www.benzinga.com/news/24/08/40643211/trump-doesnt-mince-words-about-mark-zuckerberg-in-his-new-coffee-table-book-he-would-come-to-the-ova">new coffee table book</a>, saying, &#8220;He would bring his very nice wife to dinners, be as nice as anyone could be, while always plotting to install shameful Lock Boxes in a true PLOT AGAINST THE PRESIDENT.&#8221;
Despite these controversies, Zuckerberg&#8217;s wealth has <a href="https://www.benzinga.com/startups/24/09/40882577/mark-zuckerbergs-wealth-skyrockets-by-51-billion-this-year-putting-him-on-track-to-claim-the-title-o">skyrocketed by $51 billion this year</a>, putting him on track to become the richest person on Earth.
Check out more of Benzinga's Consumer Tech coverage by&nbsp;<a href="https://www.benzinga.com/topic/consumer-tech" target="_blank" rel="noreferrer noopener">following this link</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/24/09/40999352/steve-jobs-and-steve-wozniak-once-pranked-the-pope-by-pretending-to-be-henry-kissinger-im-just-calli?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Steve Jobs And Steve Wozniak Once Pranked The Pope By Pretending To Be Henry Kissinger: &#8216;I&#8217;m Just Calling To Make A Confession,&#8217; Said One Apple Co-Founder</a></li>
</ul>
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo courtesy: Ray-Ban

Tech

Media

Mark Zuckerberg Has Given Up On Politics After A Barrage Of Backlash Against Meta And Himself: Here's What He Identifies As Now

Former President Donald Trump said on Tuesday that he would <a href="https://www.benzinga.com/news/24/09/40913456/trump-vows-200-tariffs-on-chinese-made-cars-in-mexico-warns-of-us-auto-industry-collapse-if-kamala-h">impose 100% tariffs</a> on every car imported into the U.S. from Mexico if elected President in the upcoming Nov. 5 elections.
What Happened: &#8220;We will put a 100% tariff on every single car coming across the Mexican border. The only way they'll get rid of that tariff is if they want to build a plant right here in the United States, with you people operating that plant.&#8221; Trump said while addressing a rally in Savannah, Georgia.
Automakers including Ford Motor Co, Chrysler parent Stellantis NV, and General Motors currently produce cars in Mexico. EV giant Tesla Inc was also considering putting up a factory in Mexico but paused it citing possible changes in policy and tariffs after the elections. 
Why It Matters: Last week, Trump pledged to <a href="https://www.benzinga.com/news/24/09/40913456/trump-vows-200-tariffs-on-chinese-made-cars-in-mexico-warns-of-us-auto-industry-collapse-if-kamala-h">impose 200% tariffs </a>on vehicles manufactured by Chinese automakers in Mexico and imported into the U.S.
Trump's tariff proposals have been a recurring theme in his campaign. He has previously said that imposing high tariffs on products made outside the country will force companies to manufacture within the U.S., thereby increasing jobs in the country. 
However, critics have pointed out that <a href="https://www.benzinga.com/news/24/09/40868156/former-democratic-senator-al-franken-says-biden-is-wrong-to-impose-higher-tariffs-on-evs-made-in-chi">heightened tariffs </a>will only be passed down to U.S. consumers and <a href="https://www.benzinga.com/news/24/09/40810978/trump-sold-us-out-with-china-tariff-policy-says-harris-in-heated-presidential-debate">won&#8217;t be borne by manufacturers</a>. 
Check out more of Benzinga&#8217;s Future Of Mobility coverage by&nbsp;<a href="https://www.benzinga.com/topic/mobility" target="_blank" rel="noreferrer noopener">following this link</a>.
Read More:
<ul>
<li><a href="https://www.benzinga.com/news/24/09/40999063/elon-musks-grok-ai-chatbot-has-no-clue-what-teslas-cybertruck-looks-like-senior-exec-calls-it-extra" target="_blank" rel="noreferrer noopener">Elon Musk&#8217;s Grok AI Chatbot Has ‘No Clue&#8217; What Tesla&#8217;s Cybertruck Looks Like: Senior Exec Calls It ‘Extra Disappointing&#8217;</a></li>
</ul>
Photo courtesy: Shutterstock

Global

Trump Pledges 100% Tariffs On All Cars Made In Mexico: 'The Only Way They'll Get Rid Of That Tariff Is…'

AOSL

Alpha And Omega Semiconductor Announced The Release Of Its AOZ1390DI-01 And AOZ1390DI-02 Ideal Diode Protection Switches

ALVO

Alvotech Announced The Initiation Of A Confirmatory Patient Study For AVT16, A Biosimilar Candidate To Entyvio (vedolizumab)

Huize Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HUIZ#NASDAQ">HUIZ</a>) reported $38.94 million in sales this quarter. This is a 23.32 percent decrease over sales of $50.77 million the same period last year.

HUIZ

Huize Holding Q2 Sales $38.94M Down From $50.77M YoY

Federal Trade Commission (FTC) Chair Lina Khan has raised concerns about the potential misuse of AI by airlines to charge <a href="https://www.benzinga.com/general/entertainment/24/09/40697540/oasis-fans-furious-as-dynamic-pricing-pushes-ticket-prices-sky-high-its-just-not-fair-says-">higher prices for passengers attending funerals</a>.
What Happened: Speaking at the 2024 Fast Company Innovation Festival, Khan highlighted the risks AI poses in enabling fraud and price discrimination. She emphasized that AI tools are accelerating scams and allowing personalized pricing based on consumer data, Business Insider <a href="https://www.businessinsider.in/tech/news/ftc-chair-lina-khan-warns-that-airlines-might-one-day-use-ai-to-find-out-youre-attending-a-funeral-and-charge-more/articleshow/113608485.cms">reported</a> on Wednesday.
Khan explained that AI is already automating traditional online scams like phishing and introducing new frauds such as voice cloning. She also warned about retailers using AI-driven surveillance technology to adjust prices for specific shoppers.
The FTC is investigating AI&#8217;s role in price discrimination, which differs from dynamic pricing which adjusts prices based on market conditions. Khan noted that AI could lead to varied prices based on personal data collected by digital companies.
She provided examples, such as people with nut allergies being charged more for granola bars or restaurants using QR codes for personalized menus. 
&#8220;Or somebody being charged more for an airplane ticket because the company knows that they just had a death in the family and need to fly across the country,&#8221; Khan said.
In July, the FTC issued a market inquiry to eight companies to provide information on &#8220;surveillance pricing products and services&#8221; that use consumer data. Khan stressed the importance of examining this practice to determine its impact on consumers.
Khan concluded by questioning whether society wants to accept such targeted pricing or implement regulations to prevent it. She also noted that dynamic pricing in areas like ride-sharing has made people more accustomed to variable pricing.
See Also: <a href="https://www.benzinga.com/news/24/09/40971831/putin-ally-who-unveiled-tesla-cybertruck-with-machine-gun-last-month-now-says-elon-musk-remotely-dis?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Putin Ally Who Unveiled Tesla Cybertruck With Machine Gun Last Month Now Says Elon Musk &#8216;Remotely Disabled&#8217; The Militarized EV</a>
Why It Matters: The concerns raised by Khan about AI-driven price discrimination come amid broader scrutiny of tech companies&#8217; data practices. 
Last week, the FTC criticized major tech firms like Amazon.com Inc. and Meta Platforms Inc. for their extensive data collection and monetization practices, which <a href="https://www.benzinga.com/government/24/09/40946073/no-privacy-for-profits-sake-ftc-calls-out-amazon-meta-big-tech-for-exposing-users-to-host-of-harms">pose significant privacy risks to consumers</a>.
Moreover, in December CNBC&#8217;s &#8220;Mad Money&#8221; host Jim Cramer criticized Khan&#8217;s policies, arguing that her <a href="https://www.benzinga.com/analyst-ratings/analyst-color/23/12/36295790/jim-cramer-slams-ftc-chair-lina-khans-policies-for-hampering-investor-returns-one-w">stance on mergers and acquisitions</a> is negatively impacting investor returns. Cramer referred to her as a &#8220;one-woman wrecking crew&#8221; for stock portfolios, highlighting the tension between regulatory oversight and market performance.
Additionally, in July 2023, Elon Musk accused Khan of <a href="https://www.benzinga.com/government/23/07/33218387/twitters-elon-musk-accuses-ftcs-lina-khan-of-bias-and-overreach-seeks-to-end-privacy-investigation">bias and overreach in the FTC&#8217;s privacy investigation</a> into Twitter (Now known as X). Musk&#8217;s allegations underscore the contentious relationship between the FTC and tech giants, as they navigate the complex landscape of data privacy and consumer protection.
In April, Apple Inc. was called out by Jon Stewart for allegedly blocking an interview with Khan on his podcast. This incident highlights the ongoing antitrust investigations into Apple&#8217;s <a href="https://www.benzinga.com/news/24/04/38062028/please-dont-talk-to-her-apple-called-out-by-jon-stewart-for-blocking-ftc-chair-lina-khans-interview">business practices and market dominance</a>.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/24/09/40950674/data-scientist-who-called-2020-election-correctly-says-its-gone-from-drastic-landslide-in-trumps-dir?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Data Scientist Who Called 2020 Election Correctly Says Its Gone From &#8216;Drastic Landslide In Trump&#8217;s Direction To A Drastic Landslide For Harris&#8217;</a></li>
</ul>
Image Via Shutterstock 
This story was generated using <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a> and edited by <a href="https://www.benzinga.com/topic/Kaustubh-Bagalkote" target="_blank" rel="noreferrer noopener">Kaustubh Bagalkote</a>

Equities

AAPL

AMZN

FTC Chair Lina Khan Warns Airlines May Exploit AI For Price Discrimination, Raising Concerns Over Targeting Vulnerable Travelers

Democratic Party candidate Kamala Harris <a href="https://www.benzinga.com/news/24/09/40974653/trump-vs-harris-vice-president-leads-in-2-more-new-polls-but-pollster-says-undecided-republicans-can">may be riding on the high of the strong impact</a> she has created among voters ever since she replaced President Joe Biden on the Democratic ticket in late July. But she can&#8217;t count on the support of Sen. Joe Manchin (I-W.Va.), who was a Democrat until May this year and has since then registered as an independent, refused to endorse her.
What Happened: Manchin&#8217;s stance against Harris comes as the Vice President said in an interview with Wisconsin Public Radio that she was in favor of bypassing the Senate&#8217;s filibuster rule if it was needed to protect abortion rights. A Senate filibuster is an attempt to delay or block a vote on a piece of legislation
In an interview with CNN, Manchin, who is a conservative in ideology, <a href="https://edition.cnn.com/2024/09/24/politics/joe-manchin-not-endorse-harris-filibuster/index.html">said</a>, &#8220;She knows the filibuster is the holy grail of democracy. It's the only thing that keeps us talking and working together. If she gets rid of that, then this would be the House on steroids.&#8221;
Manchin said he would not endorse Harris as he was of the view that the elimination of filibusters would destroy the country. &#8220;My country is more important for me than any one person or any one person&#8217;s ideology,&#8221; he said.
<a href="https://benzinga.grsm.io/register174">Benzinga </a>has reached out to the senator&#8217;s press team and Harris&#8217; campaign for clarification and will update the story on receipt of a response from them.
See Also: <a href="https://www.benzinga.com/government/24/05/38779387/joe-manchin-expresses-disappointment-in-congress-inaction-over-nations-rising-35-trillion-debt-its-a">Joe Manchin Expresses Disappointment In Congress&#8217; Inaction Over Nation&#8217;s Rising $35 Trillion Debt: &#8216;It&#8217;s A Shame &#8230; No One Cares About It&#8217;</a>
Why It&#8217;s Important: An earlier attempt by Biden in 2022 to restore abortion as a constitutional right by making an exception to the filibuster fell through due to a lack of support from Manchin and Sen. Kyrsten Sinema (I-Ariz.).
The Senate has already dropped the 60-vote threshold for confirming judicial and executive branch nominees.
Manchin is set to retire after his current term. Although an independent, he continues to caucus with Democrats. He had previously expressed his willingness to endorse Harris contingent on her stance on filibustering aligns with his.
Read Next:
<ul>
<li>Did You Know? Congress Is Making Huge Investments.&nbsp;<a href="https://www.benzinga.com/gov-trades" target="_blank" rel="noreferrer noopener">Get Tips On What They Bought And Sold Ahead Of The 2024 Election With Our Easy-to-Use Tool</a></li>
</ul>
Image Via Shutterstock

Government

Regulations

Long-Time Democrat Turned Independent Joe Manchin Withholds Endorsement For Kamala Harris: 'This Would Be House On Steroids' Says Senator, If Vice President Gets Rid Of Filibuster

SPGI

Platts, Part Of S&P Global Commodity Insights, Announced The Upcoming Launch Of First Daily Carbon-accounted Iron Ore Price Assessments And Related Carbon Intensity Estimates To Bring Greater Transparency To The Industry's Decarbonization Efforts

Global financial services company The Bank of New York Mellon Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BK#NYSE">BK</a>) secured an exception from the U.S. Securities and Exchange Commission&#8217;s (SEC) contentious SAB 121 rule, paving the way for its entry into the lucrative but largely untapped cryptocurrency custody market.
What Happened: The regulator did not raise any objections to BNY&#8217;s plan to safeguard cryptocurrency assets for its exchange-traded product clients, without reflecting these assets on the bank&#8217;s balance sheet, Bloomberg <a href="https://www.bloomberg.com/news/articles/2024-09-24/bny-plans-to-custody-crypto-for-etfs-after-sec-review">reported</a> Tuesday.
This is a significant development considering the ongoing debate around the SEC&#8217;s SAB 121 rule, which mandates that companies holding customers' cryptocurrencies <a href="https://www.benzinga.com/markets/cryptocurrency/24/05/38880951/senate-votes-to-overturn-controversial-sec-crypto-rule-but-will-biden-veto-it">must record them on their balance sheets</a>. Banks have been critical of this rule, arguing that it hampers their ability to custody digital assets.
See Also: <a href="https://www.benzinga.com/markets/cryptocurrency/24/09/41017645/elon-musk-applauds-pro-bitcoin-el-salvador-president-nayib-bukele-for-un-address-we-do-not">Elon Musk Applauds Pro-Bitcoin El Salvador President Nayib Bukele For UN Address</a>
BNY clarified that the SEC&#8217;s non-objection is limited to its ETP use case and does not address the broader issue of SAB 121 restricting bank custody of digital assets. The bank intends to continue its engagement with the Office of the Chief Accountant (OCA) on additional use cases through the OCA&#8217;s &#8216;facts and circumstances&#8217; process.
Why It Matters: A TradFi giant, BNY holds more than $50 trillion in assets as of June 30. Its decision to step into the digital custodian market could be influenced by the successful launch of spot Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) and Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>) exchange-traded funds (ETFs) earlier this year.
Currently, the market is lop-sided, with Coinbase being the primary custodian for most ETFs. Its hegemony was challenged somewhat after Anchorage Digital Bank <a href="https://www.benzinga.com/markets/cryptocurrency/24/09/40835527/crypto-bank-anchorage-digital-challenges-coinbases-etf-custody-dominance">secured a role as custodian</a> for the&nbsp;ARK 21Shares Bitcoin ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/ARKB#BATS">ARKB</a>).
This development comes amidst a broader debate around the SEC&#8217;s SAB 121 rule. Republican lawmakers from both the Senate and House <a href="https://www.benzinga.com/markets/cryptocurrency/24/09/41007125/caitlin-long-says-progressives-are-actually-big-bank-corporatists-as-republican-lawmakers-">urged the SEC to retract this controversial accounting rule</a> for cryptocurrency assets.
It is the only cryptocurrency-related legislation to pass through the House and Senate, although it was vetoed by the White House in May.
Price Action: Shares of BNY closed 0.27% lower at $71.87 during Tuesday&#8217;s regular trading session, according to <a href="https://pro.benzinga.com/dashboard?_gl=1&#x2A;380nj0&#x2A;_ga&#x2A;MTEyOTAyOTcxMy4xNzEzMzY0NTYy&#x2A;_ga_V7ZK73W7N0&#x2A;MTcxNDk4MzIzMi42LjEuMTcxNDk4OTE0Ni4wLjAuMA..">data from Benzinga Pro</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/09/41008797/core-emerges-as-leading-bitcoin-sidechain-by-total-value-locked">Core Emerges As Leading Bitcoin Sidechain By Total Value Locked</a></li>
</ul>
Photo courtesy: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

$ETH

ARK 21Shares Bitcoin ETF ARK 21Shares Bitcoin ETF

ARKB

BNY Mellon Gets Exemption From SEC's Controversial Crypto Custody Rule: Will It Challenge Coinbase's Hegemony In Holding Assets For Bitcoin And Ethereum ETFs?

Ukrainian President Volodymyr Zelenskyy has called on Western leaders to take decisive action to compel Russia into ending the war, which he says cannot be resolved through dialogue alone. This plea comes amid accusations from the Kremlin that the United Nations is ignoring Ukraine&#8217;s alleged incursion into Russia&#8217;s Kursk region.
What Happened: Speaking at the United Nations Security Council, Zelenskyy emphasized the need for &#8220;forcing Russia into peace,&#8221; reported Reuters on Wednesday.
&#8220;This war can&#8217;t be calmed by talks. Action is needed,&#8221; Zelenskyy urged.
Zelenskyy&#8217;s <a href="https://www.benzinga.com/news/24/09/40975071/ukraines-zelenskyy-heads-to-us-to-present-victory-plan-against-russia-to-biden-as-war-drags-for-over">&#8220;victory plan&#8221; to end the war</a>, which he has been advocating to Western leaders, does not involve ceding any territory to Russia. He also accused North Korea and Iran of being &#8220;de facto accomplices&#8221; of Moscow by providing arms for the war.
Meanwhile, Russian Foreign Minister Sergei Lavrov slammed the U.N. of ignoring alleged atrocities committed by Ukrainian forces during an incursion into Russia&#8217;s Kursk region last month. 
&#8220;I have not heard any voices from U.N. representatives responsible for human rights, including, of course, the secretary general,&#8221; he said, referring to U.N. Secretary Antonio Guterres.
See Also: <a href="https://www.benzinga.com/government/24/09/40971374/elon-musk-responds-to-venture-capitalists-claim-on-government-subsidies-for-spacex-tesla-do-some-res?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Elon Musk Responds to Venture Capitalist&#8217;s Claim On Government Subsidies For SpaceX, Tesla: &#8216;Do Some Research Before You Display Your Utter Ignorance&#8217;</a>
Why It Matters: Zelenskyy&#8217;s call for Western support to force Russia into peace comes after a series of escalating tensions. Earlier this month, Russian President Vladimir Putin warned that Ukraine&#8217;s use of Western-made <a href="https://www.benzinga.com/news/24/09/40851131/russian-president-says-ukraines-use-of-long-range-missiles-would-signal-that-us-and-nato-are-at-war">long-range missiles</a> against Russia could lead to a direct military confrontation between Russia and the West. Zelenskyy had been lobbying for Western allies to permit Ukraine to deploy these missiles as a means to limit Moscow&#8217;s attack capabilities, a move that Putin argued would implicate the countries providing the missiles in the conflict.
Additionally, former U.S. President Donald Trump recently claimed that <a href="https://www.benzinga.com/news/24/09/40998738/trump-says-ukrainian-president-backs-kamala-harris-for-white-house-zelenskyy-is-the-greatest-salesma">Zelenskyy favors a Democratic win </a>in the upcoming 2024 U.S. election. This assertion contrasts with some of Trump&#8217;s allies who believe Ukraine would welcome his return, claiming he has the skills to negotiate peace with Putin.
Did You Know?
<ul>
<li>Congress Is Making Huge Investments. <a href="https://www.benzinga.com/gov-trades" target="_blank" rel="noreferrer noopener">Get Tips On What They Bought And Sold Ahead Of The 2024 Election With Our Easy-to-Use Tool</a></li>
</ul>
Disclaimer: This content was partially produced with the help of <a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noreferrer noopener">Benzinga Neuro</a> and was reviewed and published by Benzinga editors.
Photo by evan_huang on Shutterstock

Ukraine's Zelenskyy Urges West For Forcing Russia To Peace While Kremlin Slams UN For Turning A Blind Eye To Kyiv's Incursion Into Kursk

NKTR

Nektar Therapeutics Announced Several Presentations For Rezpegaldesleukin At The 2024 European Academy Of Dermatology And Venereology Congress

CLVT

Clarivate Announced The Development Of A Comprehensive Framework For Evaluating The Societal Impact Of Research

Broadridge Financial Announced That Skandinaviska Enskilda Banken Ab Is Leveraging Broadridge's International Post-trade Processing Solution To Simplify And Streamline Its Securities Business Across International And Domestic Markets

HII (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HII#NYSE">HII</a>) announced today that its Ingalls Shipbuilding division was awarded a $9.6 billion multi-ship procurement contract for the construction of three San Antonio-class (LPD 17) amphibious ships and a contract modification for the next America-class (LHA 6) large-deck amphibious ship. This combined procurement — the first of its kind for amphibious ships — begins the journey for the construction of LPDs 33, 34, 35 and LHA 10 for the U.S. Navy. &nbsp;
"We greatly appreciate the stability that this award provides to all Ingalls shipbuilders and our surrounding communities," Ingalls President Kari Wilkinson said. "It is an honor to continue our support of the joint Navy and Marine Corps mission to meet the minimum 31-amphibious-ship requirement."
Approximately half of all Ingalls shipbuilders build amphibious ships today, with another 650 supplier partners in 39 states across the country that provide components for the construction of amphibious ships.

Reported Earlier, HII Secures $9.6B Contract to Build Amphibious Ships for US Navy

VTNR

Reported Earlier, Vertex Energy Announced It Entered Into A Restructuring Support Agreement With Term Loan Lenders And Commenced Chapter 11 Cases In The United States Bankruptcy Court For The Southern District Of Texas

At&nbsp;a special briefing for policymakers on Capitol Hill today, Centrus said that the $3.4 billion that Congress has made available for domestic nuclear fuel production should be focused on deploying American uranium enrichment technology that is manufactured in the United States, by American workers, as opposed to foreign-origin centrifuge technologies that are manufactured overseas.&nbsp;
&nbsp;
&nbsp;
"The need to transition away from Russian nuclear fuel, coupled with a historic investment in U.S. nuclear fuel production approved by Congress, has created a once-in-a-generation opportunity to restore America's domestic supply chain for enriched uranium," said Amir Vexler, President and CEO of Centrus. "We should not be content to trade dependence on Russia for dependence on China, or Europe, or anywhere else. The time has come to invest in American enrichment technology, built by American workers, with an American supply chain."&nbsp;
Vexler was joined at the briefing by leaders of approximately 14 large and small businesses with work locations in 13 states, representing Centrus' nationwide supply chain. These American-owned companies and many others would provide critical components and other support to Centrus if the federal government decides to support deployment of Centrus' American Centrifuge technology, which is manufactured in Oak Ridge, Tennessee and operated in Piketon, Ohio.&nbsp;
Under contract with the U.S. Department of Energy, Centrus has deployed a cascade of sixteen centrifuges at the American Centrifuge Plant in Piketon, Ohio, and is pioneering production of an advanced reactor fuel called High-Assay, Low-Enriched Uranium (HALEU). Centrus' goal is to expand the capacity of the plant with thousands of additional centrifuges to accommodate large-scale production of Low-Enriched Uranium (LEU) for existing reactors and HALEU for next generation reactors. This will require a public private partnership including robust federal investment alongside private capital and purchase agreements from customers.&nbsp;
Centrus is competing for federal funding under a series of Requests for Proposals (RFPs) issued by the U.S. Department of Energy. These RFPs are backed by more than $3.4 billion in Congressional appropriations that were approved as part of the Inflation Reduction Act in 2022 and the bipartisan government funding bill in March 2024.&nbsp;

Centrus Urges Congress to Prioritize US-Made Nuclear Fuel Technology Amid $3.4B Funding to Cut Russian Dependency

Offerings

OCCI

Reported Earlier, OFS Credit Company Announced The Pricing Of An Underwritten Public Offering Of 1,040,000 Shares Of 7.875% Series F Term Preferred Stock Due 2029 At A Price Of $25.00 Per Share, Raising $26.0M In Gross Proceeds

Wayfair Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/W#NYSE">W</a>) (the "Company," "we" or "Wayfair") today announced the pricing by its subsidiary, Wayfair LLC (the "Issuer"), of its private offering of $800 million in aggregate principal amount of 7.250% senior secured notes due 2029 (the "Notes"). The&nbsp;offering size was increased to $800 million from the previously announced offering size of $700 million in aggregate principal&nbsp;amount&nbsp;of&nbsp;Notes. The Notes&nbsp;will mature on October 31, 2029, unless earlier repurchased or redeemed in accordance with their terms. The Notes oﬀering is expected to close on October 8, 2024, subject to customary closing conditions.
&nbsp;
We intend to use the net proceeds from the Notes oﬀering, together with cash on hand, for the repayment of certain of Wayfair's existing convertible senior notes and general corporate purposes.

Reported Earlier, Wayfair Raised $800M (Prior $700M) Via Upsized Secondary Senior Secured Notes Offering For Debt Repayment

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Silk recalls are a hot topic on Thursday as the plant-based milk alternative is being pulled from shelves <a href="https://www.foodsafetynews.com/2024/07/illnesses-prompt-nationwide-recall-of-silk-and-great-value-brand-plant-based-beverages-in-canada/">due to listeria monocytogenes&nbsp;concerns</a>.



This recall affects Silk products and Walmart&rsquo;s (NYSE:<a href="https://investorplace.com/stock-quotes/wmt-stock-quote/">WMT</a>) Great Value products sold in Canada. An outbreak of foodborne illness resulted in an investigation that spurred the recall. It&rsquo;s also possible this recall could spread to more products made by Danone Canada.



Consumers are advised not to consume, use, sell, serve or distribute products included in the recall.



Let&rsquo;s <a href="https://recalls-rappels.canada.ca/en/alert-recall/various-silk-and-great-value-brand-plant-based-refrigerated-beverages-recalled-due#tablefield-node-75799-field_affected_products-0">break down the products</a> included in these recalls below!



<h2>Silk Recalls 2024: Products Affected</h2>



First up are the Silk brand products included in the recall. They include the following with best-by dates up to 24 OC 04.



<ul><li>Almond &amp; Coconut Unsweetened with UPC 0 25293 00250 0.</li>



<li>Almond Original with UPC 0 25293 00100 8.</li>



<li>Almond Dark Chocolate with UPC 0 25293 00135 0.</li>



<li>Almond Unsweetened with UPC 0 25293 00150 3.</li>



<li>Almond Unsweetened Vanilla with UPC 0 25293 00188 6.</li>



<li>Almond Vanilla with UPC 0 25293 00168 8.</li>



<li>Coconut Original with UPC 0 25293 00152 7.</li>



<li>Coconut Unsweetened with UPC 0 25293 00244 9.</li>



<li>Oat Original with UPC 0 36632 07240 5.</li>



<li>Oat Vanilla with UPC 0 36632 07241 2.</li>



<li>Oat Dark Chocolate with UPC 0 36632 07239 9.</li>



<li>Oat Unsweetened with UPC 0 36632 07532 1.</li>



<li>Oat Unsweetened Vanilla with UPC 0 56800 72749 4.</li>



<li>Almond &amp; Cashew Unsweetened with UPC 0 36632 07235 1.</li>



<li>Almond &amp; Cashew Unsweetened Vanilla with UPC 0 36632 07234 4.</li>
</ul>Now let&rsquo;s get into those Great Value brand recalls. These have the same best-by dates as the products in the Silk recalls.



<ul><li>Almond Beverage Unsweetened Original with UPC 6 81131 34208 7.</li>



<li>Almond Beverage Original with UPC 6 81131 34209 4.</li>



<li>Almond Beverage Vanilla with UPC 6 81131 34210 0.</li>
</ul>Outside of the Silk recalls, we also have stock market stories worth reading about today.



InvestorPlace is home to all of the hottest stock market stories on Thursday! Among that is what&rsquo;s going on with shares of FuelCell Energy&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/fcel-stock-quote/">FCEL</a>), Joby Aviation&nbsp;(NYSE:<a href="https://investorplace.com/stock-quotes/joby-stock-quote/">JOBY</a>) and Kazia Therapeutics&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/kzia-stock-quote/">KZIA</a>) stock. You can find out more on these matters at the following links!



<h2>More Thursday Stock Market News</h2>



<ul><li><a href="https://investorplace.com/2024/07/fcel-stock-alert-fuelcell-energy-pops-on-korean-market-update/">FCEL Stock Alert: FuelCell Energy Pops on Korean Market Update</a></li>



<li><a href="https://investorplace.com/2024/07/joby-stock-pops-after-completing-523-mile-evtol-flight/">JOBY Stock Pops After Completing 523-Mile eVTOL Flight</a></li>



<li><a href="https://investorplace.com/2024/07/kzia-stock-alert-kazia-continues-its-surge-on-thursday-with-51-gains/">KZIA Stock Alert: Kazia Continues Its Surge on Thursday With 51% Gains</a></li>
</ul>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2024/07/silk-recalls-2024-what-to-know-as-plant-based-milk-recalled-over-listeria-concerns/">Silk Recalls 2024: What to Know as Plant-Based Milk Recalled Over Listeria Concerns</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Silk Recalls 2024: What to Know as Plant-Based Milk Recalled Over Listeria Concerns

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Pre-market stock movers are worth keeping an eye on and we have a breakdown of all the biggest ones to watch on Friday!



Moving stocks are mergers, clinical trial data, public offerings and more.



Let&rsquo;s get into that news below!



<h2>Biggest Pre-Market Stock Movers: 10 Top Gainers</h2>



<ol><li>Crown LNG (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGBS#NASDAQ">CGBS</a>) stock is rocketing almost 154% after <a href="https://finance.yahoo.com/news/crown-lng-holding-announces-completion-201700767.html">recently completing a business combination</a>.</li>



<li>Toyo (NASDAQ:<a href="https://investorplace.com/stock-quotes/toyo-stock-quote/">TOYO</a>) shares are soaring close to 111% alongside heavy pre-market trading.</li>



<li>Sentage (NASDAQ:<a href="https://investorplace.com/stock-quotes/sntg-stock-quote/">SNTG</a>) stock is surging over 60% with strong early morning trading.</li>



<li>Above Food Ingredients (NASDAQ:<a href="https://investorplace.com/stock-quotes/abve-stock-quote/">ABVE</a>) shares are increasing more than 42% without any clear news this morning.</li>



<li>Monterey Capital Acquisition (NASDAQ:<a href="https://investorplace.com/stock-quotes/mcac-stock-quote/">MCAC</a>) stock is gaining over 23% on Friday morning.</li>



<li>Maxeon Solar Technologies (NASDAQ:<a href="https://investorplace.com/stock-quotes/maxn-stock-quote/">MAXN</a>) shares are rising more than 19% with heavy early morning trading.</li>



<li>Qualigen Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/qlgn-stock-quote/">QLGN</a>) stock is heading nearly 16% higher with strong pre-market trading.</li>



<li>Immutep (NASDAQ:<a href="https://investorplace.com/stock-quotes/immp-stock-quote/">IMMP</a>) shares are climbing over 15% with <a href="https://www.nasdaq.com/market-activity/stocks/immp/press-releases">positive clinical results</a>.</li>



<li>Big Tree Cloud (NASDAQ:<a href="https://investorplace.com/stock-quotes/dsy-stock-quote/">DSY</a>) stock is jumping more than 14% on Friday.</li>



<li>Instil Bio (NASDAQ:<a href="https://investorplace.com/stock-quotes/til-stock-quote/">TIL</a>) shares are up over 14% today.</li>
</ol><h2>10 Top Losers</h2>



<ol><li>Shineco (NASDAQ:<a href="https://investorplace.com/stock-quotes/sisi-stock-quote/">SISI</a>) stock is crashing more than 44% on a <a href="https://www.nasdaq.com/press-release/shineco-announces-proposed-underwritten-public-offering-2024-07-11">proposed public offering</a>.</li>



<li>ASP Isotopes (NASDAQ:<a href="https://investorplace.com/stock-quotes/aspi-stock-quote/">ASPI</a>) shares are diving over 19% as it also announces a <a href="https://www.globenewswire.com/news-release/2024/07/11/2912107/0/en/ASP-Isotopes-Announces-Proposed-Public-Offering-of-Common-Stock.html">proposed public offering</a>.</li>



<li>Cyngn (NASDAQ:<a href="https://investorplace.com/stock-quotes/cyn-stock-quote/">CYN</a>) stock is tumbling 18% following a <a href="https://www.nasdaq.com/press-release/more-1bn-annual-sales-alta-equipment-group-joins-cyngns-dealer-network-2024-07-11">massive rally yesterday</a>.</li>



<li>Kazia Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/kzia-stock-quote/">KZIA</a>) shares are retreating more than 16% <a href="https://investorplace.com/2024/07/kzia-stock-alert-kazia-continues-its-surge-on-thursday-with-51-gains/">after rallying this week</a>.</li>



<li>Nano Nuclear Energy (NASDAQ:<a href="https://investorplace.com/stock-quotes/nne-stock-quote/">NNE</a>) stock is taking an over 12% beating after <a href="https://www.nasdaq.com/press-release/nano-nuclear-energy-announces-pricing-upsized-18-million-underwritten-offering-2024">pricing an upsized underwritten offering</a>.</li>



<li>Biodexa Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/bdrx-stock-quote/">BDRX</a>) shares are falling more than 10% after jumping yesterday on <a href="https://seekingalpha.com/news/4123698-biodexa-stock-rallies-amid-release-of-phase-2-data-for-erapa">clinical trial data</a>.</li>



<li>Digital Brands Group (NASDAQ:<a href="https://investorplace.com/stock-quotes/dbgi-stock-quote/">DBGI</a>) stock is dropping over 10% this morning.</li>



<li>Sonoma Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/snoa-stock-quote/">SNOA</a>) shares are decreasing more than 10% following a Thursday rally.</li>



<li>Forward Industries (NASDAQ:<a href="https://investorplace.com/stock-quotes/ford-stock-quote/">FORD</a>) stock is dipping 10% without any news to report.</li>



<li>Nuwellis (NASDAQ:<a href="https://investorplace.com/stock-quotes/nuwe-stock-quote/">NUWE</a>) shares close out our pre-market stock movers down over 9% this morning.</li>
</ol>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2024/07/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-friday-july-12th/">Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
If you&rsquo;ve read all the warnings and still want to jump into some of the top <a href="https://investorplace.com/stock-types/penny-stocks/">penny stocks</a> to buy, focus on the key fundamentals.



That includes its earnings numbers, business models, product pipelines and what market they&rsquo;re part of.&nbsp;



You&rsquo;ll also want to pay close attention to volume, especially volume spikes. That&rsquo;s because volume often precedes price. In addition, you&rsquo;ll also want to see if the volume is being supported by news. Or you&rsquo;ll get what we just saw with Zapp Electric (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZAPP#NASDAQ">ZAPP</a>).



Over the last few days, ZAPP ran from about $2 to $19.10 on heavy volume &mdash; but no news.



On July 2, it traded at $2.04 and saw volume spike to 35.2 million, as compared to average volume of 7.2 million. On July 3, volume jumped to 25.5 million.



By July 5, it was up to 50.3 million. Then by July 8, volume soared to 105 million. And by July 9, volume was up 45 million. Now, as volume fades, the stock is starting to pull back.&nbsp;While it was fun to watch, it won&rsquo;t end well &mdash; especially for the stock-chasing bag holders.



Here are a few &ldquo;safer&rdquo; penny stocks to buy instead.



<h2>Kazia Therapeutics (KZIA)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/03/pharmaceuticals_tnxp_1600-300x169.png" alt="medicine research, pharmaceutical background, LJPC stock"><div>Source: Sisacorn / Shutterstock.com</div></div>Keep an eye on penny stocks to buy such as Kazia Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KZIA#NASDAQ">KZIA</a>). Even after exploding from 20 cents to a high of $1.08, it could push aggressively higher.&nbsp;



All after it posted <a href="https://www.biospace.com/article/releases/kazia-therapeutics-announces-phase-ii-iii-clinical-trial-results-for-paxalisib-in-glioblastoma/">positive Phase 2/3 results</a> for its drug paxalisib in the treatment of glioblastoma, which is a malignant tumor affecting the brain or spine. The study, called GBM-AGILE, showed a median overall survival of&nbsp;14.77 months for paxalisib-treated patients, as compared to 13.84 months for those given the standard of care.



With that, the company said it will request a meeting with the U.S. FDA to see if it can get accelerated approval.&nbsp;



As noted by <a href="https://www.biospace.com/article/releases/kazia-therapeutics-announces-phase-ii-iii-clinical-trial-results-for-paxalisib-in-glioblastoma/">Kazia CEO&nbsp;Dr.&nbsp;John Friend</a>, &ldquo;We are excited to have shown a 3.8-month improvement in overall survival, an approximate 33% improvement, for newly diagnosed unmethylated patients with GBM compared to the concurrent standard of care arm. Having comparable Overall Survival data across two independent studies is a compelling outcome in this difficult-to-treat glioblastoma population.&rdquo;



<h2>Curaleaf Holdings (CURLF)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2024/04/cannabis-stocks1600-3-300x169.png" alt="scientist checking organic hemp wild plants in a cannabis weed commercial greenhouse. Concept of herbal alternative medicine, cbd oil, pharmaceutical industry. Cannabis stocks, FLGC stocks"><div>Source: Chokniti-Studio / Shutterstock.com</div></div>At a bit over $4, Curaleaf Holdings (OTCMKTS:<a href="https://investorplace.com/stock-quotes/curlf-stock-quote/">CURLF</a>) is a strong buy on three key cannabis catalysts.



As I noted on July 8, &ldquo;We already know&nbsp;<a href="https://www.pewresearch.org/short-reads/2024/04/10/facts-about-marijuana/#:~:text=An%20overwhelming%20majority%20of%20U.S.,and%20recreational%20use%20(57%25).">88% of Americans</a>&nbsp;want legalization, which the current candidates should use to their advantage for votes. We know cannabis will be rescheduled as a Schedule III drug at some point.&nbsp;And we know that Florida will vote on legalization.&rdquo;



If Florida votes for legalization, it could unlock a massive market opportunity. All are potentially powerful catalysts.



Helping,&nbsp;<a href="https://www.newcannabisventures.com/curaleaf-q1-revenue/">according to Curaleaf CEO Matt Darin</a>, &ldquo;Our unique exposure to the most significant catalysts on the horizon &mdash; continued expansion of the NY market, expansion of Pillar 1 in&nbsp;Germany, and adult use in&nbsp;Ohio,&nbsp;Florida and&nbsp;Pennsylvania&nbsp;sets us up for robust growth in 2025 and beyond.&rdquo;



Last trading at around $4.16, I&rsquo;d use the recent weakness as an opportunity as we near the election.



<h2>Plug Power (PLUG)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2024/03/plug1600-7-300x169.png" alt="In this photo illustration, the Plug Power logo is displayed on a smartphone screen"><div>Source: rafapress / Shutterstock.com</div></div>We can also look at down, but not out shares of hydrogen stock, Plug Power (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLUG#NASDAQ">PLUG</a>).



After finding strong support at around $2.21, PLUG now trades at $3.02 and could push higher.&nbsp;Helping, the company just&nbsp;<a href="https://www.ir.plugpower.com/press-releases/news-details/2024/Plug-Completes-13-Hydrogen-Refueling-Station-Deployments-Over-Last-Two-Years-in-Europe/default.aspx#:~:text=SLINGERLANDS%2C%20N.Y.%2C%20July%2010%2C,last%20two%20years%20across%20Europe.">deployed 13 hydrogen refueling stations across Europe.</a> While most are still in the commissioning phase, all are expected to be operational this summer.



Even better, the company said it saw a &ldquo;<a href="https://seekingalpha.com/news/4092367-plug-power-touts-substantial-advancement-in-hydrogen-generation-buildout">substantial advancement</a>&rdquo; with its plants in Georgia and Tennessee. It also noted that its Louisiana joint venture with&nbsp;Olin&nbsp;(NYSE:<a href="https://investorplace.com/stock-quotes/oln-stock-quote/">OLN</a>) is on track to see mechanical completion by the end of the third quarter.



Plus, it just signed&nbsp;<a href="https://www.globenewswire.com/news-release/2024/04/25/2869470/9619/en/Plug-Signs-Additional-BEDP-Contracts-for-a-Total-of-4-5GW-of-Electrolyzers-Across-Europe-and-the-United-States.html">two contracts</a>&nbsp;to deliver basic engineering and design packages for projects in Europe and the U.S.



Moreover, when and if we see changes to restrictive 45V industry tax credits, Plug Power and other top <a href="https://investorplace.com/industries/energy/renewable-energy/hydrogen/">hydrogen stocks</a> could race to higher highs.



On Penny Stocks and Low-Volume Stocks:&#8239;With only the rarest exceptions,&nbsp;InvestorPlace&nbsp;does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That&rsquo;s because these &ldquo;penny stocks&rdquo; are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that&#8239;InvestorPlace.com&rsquo;s&nbsp;writers disclose this fact and warn readers of the risks.



Read More:&#8239;<a href="https://investorplace.com/2014/05/fraud-penny-stocks-scams/" target="_blank">Penny Stocks &mdash;&nbsp;How to Profit Without Getting Scammed</a>



On the date of publication, Ian Cooper did not hold (either directly or indirectly) any positions in the securities mentioned. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/?utm_source=Nasdaq&amp;utm_medium=referral">Publishing Guidelines</a>.



On the date of publication, the responsible editor did not have (either directly or indirectly) any positions in the securities mentioned in this article.
<div>Ian Cooper, a contributor to InvestorPlace.com, has been analyzing stocks and options for web-based advisories since 1999.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	
The post <a href="https://investorplace.com/2024/07/from-pennies-to-dollars-3-sub-5-stocks-set-to-explode-higher/">From Pennies to Dollars: 3 Sub-$5 Stocks Set to Explode Higher</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

From Pennies to Dollars: 3 Sub-$5 Stocks Set to Explode Higher

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Biotechnology stock traders, listen up! Do you like to roll the dice and take your chances on promising drug developers? If so, then you&rsquo;ll definitely want to add Kazia Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/kzia-stock-quote/">KZIA</a>) to your watch list. I can&rsquo;t guarantee any safety whatsoever, but Kazia Therapeutics stock offers excitement and the possibility of substantial profits.



Or, Kazia Therapeutics might not secure full regulatory approval for its primary product, and the stock could go nowhere or just go to zero. Nearly any outcome is plausible in the wild world of <a href="https://investorplace.com/industries/healthcare/biotech/">biotech stocks</a>. So, I invite you to discover Kazia Therapeutics and decide if your stomach can handle the volatility and unpredictability.



<h2>Why Kazia Therapeutics Stock Went Bananas</h2>



Just to recap, Australian biotechnology business Kazia Therapeutics develops oncology (cancer and tumor fighting) drugs. One of Kazia Therapeutics&rsquo; drug-development programs is <a href="https://finance.yahoo.com/news/kazia-therapeutics-announces-phase-ii-113000064.html">EVT801</a>. This was found in preclinical research to be &ldquo;active against a broad range of tumour types.&rdquo;



Not to discount the importance of EVT801, but Kazia Therapeutics&rsquo; primary drug in development is <a href="https://finance.yahoo.com/news/kazia-therapeutics-announces-phase-ii-113000064.html">paxalisib</a>. Recently, Kazia Therapeutics completed a phase II/III study of paxalisib in the treatment of a type of brain cancer type called glioblastoma.



Kazia Therapeutics CEO John Friend&nbsp;proudly announced the results of the clinical trial. Paxalisib demonstrated a &ldquo;3.8 month improvement in overall survival, an approximate 33% improvement&rdquo; for selected glioblastoma patients when &ldquo;compared to the concurrent standard of care arm.&rdquo;



Furthermore, Kazia Therapeutics was well tolerated in the study. Thus, this is huge news for Kazia Therapeutics as paxalisib is the company&rsquo;s flagship product.



Kazia Therapeutics stock skyrocketed from 20 cents per share to a 52-week high of $1.58. However, the stock then sank to 53 cents. By the time you read this, the share price may be much higher or lower than that.



<h2>What&rsquo;s Next for Kazia Therapeutics?</h2>



I expect the Kazia Therapeutics share price to level off as the buyers and sellers start to calm down in the coming days. Going forward, investors should consider what&rsquo;s next for Kazia Therapeutics and paxalisib.



Two events could be make-or-break for Kazia Therapeutics. First of all, Kazia Therapeutics expects to release the full data from the paxalisib research study &ldquo;at a scientific meeting later this year.&rdquo; Heaven only knows when this will actually take place, so I won&rsquo;t attempt to make any predictions.



Kazia Therapeutics stated that it will request a meeting with the U.S. Food and Drug Administration to &ldquo;discuss the results and determine if a potential path to accelerated approval is appropriate for paxalisib.&rdquo; 



Full FDA approval is the gold standard for proposed drugs in the U.S., so keep an eye out for further developments on this news story.



<h2>Kazia Therapeutics Stock: Predict Nothing and Protect Your Wealth</h2>



Some stock traders probably enjoyed quick gains after Kazia Therapeutics released its positive clinical-trial results. Yet, some ill-timed traders may have lost money. It just goes to show that biotech stocks can be highly unpredictable and risky.



Hence, I don&rsquo;t recommend trying to predict with 100% confidence whether Kazia Therapeutics will get full FDA approval for paxalisib in treating glioblastoma patients. 



Instead, if you appreciate the company&rsquo;s promising clinical work, consider buying Kazia Therapeutics stock. At the same time, be sure to protect your wealth by only taking a very small share position.



On the date of publication, David Moadel&nbsp;did not have (either directly or indirectly) any positions in the securities mentioned in this article.&nbsp;The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.



On the date of publication, the responsible editor did not have (either directly or indirectly) and positions in the securities mentioned in this article.
<div>David Moadel has provided compelling content &ndash; and crossed the occasional line &ndash; on behalf of Motley Fool, Crush the Street, Market Realist, TalkMarkets, TipRanks, Benzinga, and (of course) InvestorPlace.com. He also serves as the chief analyst and market researcher for Portfolio Wealth Global and hosts the popular financial YouTube channel Looking at the Markets.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/2024/07/biotech-stock-laboratory-try-a-small-experiment-with-kazia-therapeutics/">Biotech Stock Laboratory: Try a Small Experiment With Kazia Therapeutics</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Biotech Stock Laboratory: Try a Small Experiment With Kazia Therapeutics

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Australian biotech company Kazia Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/kzia-stock-quote/">KZIA</a>) stock rocked the market after reporting encouraging results from a Phase II/III trial for its glioblastoma brain cancer therapy Paxalisib.&nbsp;



The positive results extended the life of patients by over three months compared to the current standard of care. Because the patients were a difficult-to-treat population, the results gave the oncology biotech developer cause to arrange a meeting with the Food &amp; Drug Administration (FDA) to pursue an accelerated pathway for approval.



As a result, Kazia Therapeutics stock surged 730% on the news, jumping from 19 cents per share to as high as $1.58 before eventually tumbling lower. Shares stand 110% above where they traded before it posted the results.



Because glioblastoma treatment is seen as a <a href="https://www.pharmiweb.com/press-release/2024-03-25/glioblastoma-treatment-market-expected-to-reach-usd-103-billion-by-2032-marketresearchbiz">$10 billion market opportunity</a> according to some estimates, producing a treatment that is better than the current level of care is a major achievement.&nbsp;



As such, there are numerous avenues for Kazia Therapeutics to exploit this market if Paxalisib gains approval. What can&rsquo;t be ignored is the possibility a pharmaceutical giant that is looking to bolster its portfolio of oncology drugs could step up and acquire Kazia Therapeutics stock.



<h2>A New Lease on Life</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/02/cells-microscope-300x169.png" alt="An image of cells under a microscope"><div>Source: pinkeyes/Shutterstock</div></div>Glioblastoma (GBM) is reportedly <a href="https://www.aans.org/patients/conditions-treatments/glioblastoma-multiforme/">one of the most common</a> and aggressive forms of brain cancer. It represents nearly half of all brain cancers. Tumors form in the brain or spinal cord though they most often occur in the frontal and temporal lobes. Left untreated, GBM can be fatal in six months or less.



Kazia Therapeutics&rsquo; Paxalisib is its<a href="https://www.prnewswire.com/news-releases/kazia-therapeutics-announces-phase-iiiii-clinical-trial-results-for-paxalisib-in-glioblastoma-302193414.html"> lead drug candidate</a> and has been the subject of 10 clinical trials for this disease. The FDA previously granted the therapy Orphan Drug status in 2018 and it gained fast-track designation in 2020. It has received various other designations from the regulatory authorities for various diseases.



In the Phase II/III study, Paxalisib resulted in a median survival rate of over 15.5 months compared to 11.9 months under the current standard of care. This is in line with an earlier Phase II study that found similar longevity by administering Paxalisib.



<h2>A Hotbed of M&amp;A Activity</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/10/mergers-acquisitions-300x169.jpg" alt='The letters "M&amp;A" on a wooden table, surrounded by a calculator and other business items. Representing IEA stock.'><div>Source: Shutterstock.com</div></div>According to analysts at White &amp; Case, the field of oncology is setting a fire underneath mergers and acquisitions. Dealmaking will <a href="https://mergers.whitecase.com/highlights/oncology-dealmaking-fuels-biotech-ma#!">reach $375 billion</a> in 2027 as demand for treatments grows.



In less than a year, Bristol Myers Squibb (NYSE:<a href="https://investorplace.com/stock-quotes/bmy-stock-quote/">BMY</a>) acquired Mirati Therapeutics for $5.8 billion to gain possession of its <a href="https://investorplace.com/2024/06/treasure-hunt-3-small-cap-stocks-wall-street-hasnt-discovered-yet/">lung cancer treatment</a>. It also paid $800 million upfront to China&rsquo;s SystImmune for its signal-blocking therapy for cancer cells. It could be worth up to $8.4 billion.



AbbVie (NASDAQ:<a href="https://investorplace.com/stock-quotes/abbv-stock-quote/">ABBV</a>) also <a href="https://investorplace.com/2024/04/these-3-small-cap-stocks-are-up-304-in-2024-can-they-run-higher/">acquired ImmunoGen for $10 billion</a> and Johnson &amp; Johnson (NYSE:<a href="https://investorplace.com/stock-quotes/jnj-stock-quote/">JNJ</a>) bought Ambrx Biopharma for $2 billion. Previously, AstraZeneca (NYSE:<a href="https://investorplace.com/stock-quotes/azn-stock-quote/">AZN</a>), Gilead Sciences (NASDAQ:<a href="https://investorplace.com/stock-quotes/gild-stock-quote/">GILD</a>) and Merck (NYSE:<a href="https://investorplace.com/stock-quotes/mrk-stock-quote/">MRK</a>) all made acquisitions in the cancer space to shore up their portfolios.



As patent expirations approach a critical stage for pharmaceutical stocks, Kazia Therapeutics could gain attention for Paxalisib.



<h2>Still a Risky Bet</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2021/08/doctor_medicine_dna_1600-300x169.jpg" alt="Various graphical representations of medical imagery are shown in front of a doctor using a tablet computer. DNA stock"><div>Source: Shutterstock / PopTika</div></div>Kazia Therapeutics stock has now traded in the 40-cent per share range for several days. Most of the gains were wrung out of the stock immediately after the results were published.



There could be a more massive upside in KZIA shares. Yet it still has the late-stage trials to go through, gaining permission from the FDA for fast-track approval and ultimately getting marketing approval.



Each step could excite the stock market again if the results are just as positive. Arguably staking a small claim to Kazia Therapeutics stock isn&rsquo;t a bad idea. I wouldn&rsquo;t go all-in because biotech investing is risky and full of unknowns. But for the speculative portion of your portfolio, buying a small tranche of the stock might not be a bad idea.



On the date of publication, Rich Duprey did not hold (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com <a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/">Publishing Guidelines</a>.



On the date of publication, the responsible editor did not have (either directly or indirectly) any positions in the securities mentioned in this article.
<div>Rich Duprey has written about stocks and investing for the past 20 years. His articles have appeared on Nasdaq.com, The Motley Fool, and Yahoo! Finance, and he has been referenced by U.S. and international publications, including MarketWatch, Financial Times, Forbes, Fast Company, USA Today, Milwaukee Journal Sentinel, Cheddar News, The Boston Globe, L&rsquo;Express, and numerous other news outlets.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>
The post <a href="https://investorplace.com/2024/07/kazia-therapeutics-stock-is-kzia-a-buyout-candidate-in-the-making/">Kazia Therapeutics Stock: Is KZIA a Buyout Candidate in the Making?</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Kazia Therapeutics Stock: Is KZIA a Buyout Candidate in the Making?

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
While investing in the best&nbsp;<a href="https://investorplace.com/stock-types/blue-chip-stocks/" target="_blank">blue chip stocks</a>&nbsp;to anchor your portfolio is always a good idea, I am always looking to diversify. A good way to do that is to invest in lesser-known but quality stocks under $10.



Lower-priced stocks have the advantage of being affordable so that you can buy more shares with less money. It&rsquo;s much cheaper to buy 100 shares of a $5 stock than to buy the same number of shares of an equity that cost $100 or more, right?



And these lower-priced stocks still can outperform the market. While the risks are higher, the rewards can be substantial, offering a tempting opportunity for investors willing to take on some level of risk.



I always suggest using the Portfolio Grader to help find the best stocks under $10. In fact, using a stock screening tool is essential in an exercise such as this.



Why? Because there are over&nbsp;<a href="https://money.usnews.com/investing/stocks/search?price-min=0&amp;price-max=10" target="_blank">2,100 stocks</a>&nbsp;on the market today are&nbsp;priced at $10 or less. No one can identify all of the best-performing stocks &ndash; or those that have the potential to perform &ndash; without using a screener like the Portfolio Grader to narrow the field.



The Portfolio Grader evaluates stocks based on various measurements, including earnings performance, growth, analyst sentiment, and momentum. The stocks under $10 on this list all score well enough to get at least a &ldquo;B&rdquo; rating in the Portfolio Grader tool.



<h2>Faraday Future Intelligent Electric (FFIE)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2023/07/ffie1600-1-300x169.png" alt="Person holding cellphone with logo of electric vehicle company Faraday Future Inc. (FFIE) on screen in front of business webpage. Focus on phone display. Unmodified photo."><div>Source: T. Schneider / Shutterstock.com</div></div>Faraday Future Intelligent Electric (NASDAQ:<a href="https://investorplace.com/stock-quotes/ffie-stock-quote/">FFIE</a>) designs, manufactures and sells electric vehicles and related products. The California company operates in the United States and China.



The company has gotten into some hot water with Nasdaq and its listing requirements because the stock is less than $1 &ndash; it has until Aug. 31 to get the stock price up &ndash; and for not always promptly filing financial reports. 



Those are red flags for sure, so already you know FFIE stock is a speculative play.



Although revenue in 2023 was only $800,000, it was the company&rsquo;s first year of revenue, as it&rsquo;s still very much a startup. Faraday delivered its first-ever vehicles in the third quarter of the year.



However, Faraday also has some interesting things in the works, as outlined in its <a href="https://investors.ff.com/news-releases/news-release-details/faraday-future-hosts-investor-community-day-and-highlights">July 20 Investor Day event</a>. Highlights included a look at the All-Ability aiHypercar, its user ecosystem, and the company&rsquo;s Auto Industry Bridge strategy.



The company raised the idea of launching a second, lower-priced automotive brand. &ldquo;A second brand could strike in the mass market with volume production, bringing everyone the &lsquo;AI car of the future&rsquo; and the &lsquo;AI car of the people&rsquo;. 



We are preparing to launch the Bridge and second brand strategies in a future event where we will share more details and our progress. We are hopeful to set sail together in the blue ocean market with potential partners,&rdquo;&nbsp;founder YT Jia said.



The company scheduled a July 31 shareholder vote that includes a proposal for a 1-for-40 reverse stock split to maintain its Nasdaq compliance. For now, FFIE stock gets a &ldquo;B&rdquo; rating in the Portfolio Grader.



<h2>SoundHound AI (SOUN)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2024/02/soun1600-1-300x169.png" alt="In this photo illustration, the SoundHound logo seen displayed on a smartphone. SOUN stock"><div>Source: rafapress / Shutterstock.com</div></div>SoundHound AI (NASDAQ:<a href="https://investorplace.com/stock-quotes/soun-stock-quote/">SOUN</a>) is an up-and-coming technology company that is using artificial intelligence and machine learning to create products that recognize and respond to verbal prompts.



SoundHound&rsquo;s platform is used by restaurants to <a href="https://investors.soundhound.com/news-releases/news-release-details/beef-o-bradys-rolls-out-soundhounds-advanced-voice-ai-ordering">automate food ordering</a>, reducing employee costs. Through its Dynamic Interaction platform, customers can verbally place complicated orders at a kiosk and pay without the intervention of an employee.



Another interesting use of SoundHound&rsquo;s platform is its employee training. Inexperienced workers can use SoundHound to ask questions about a process and SoundHound&rsquo;s AI will answer intelligently and walk the employee through the proper steps.



SoundHound also has a product that has a <a href="https://investors.soundhound.com/news-releases/news-release-details/soundhound-chat-ai-launches-peugeot-opel-and-vauxhall-vehicles">Chat AI product</a> &ndash; integrated with ChatGPT &ndash; that can manage navigation, advise about the weather or tell stories to bored children in the back seat.



I also like that SoundHound is shoring up its financial position. The company <a href="https://finance.yahoo.com/news/soundhound-ai-announces-early-debt-130000956.html">announced</a> that it reached an agreement with lenders to repay $100 million in outstanding debt. Once that&rsquo;s done, SoundHound will have zero debt and a cash balance of $180 million.



<a href="https://investors.soundhound.com/news-releases/news-release-details/soundhound-ai-reports-73-q1-revenue-growth-116-million-first">Revenue in the first quarter</a>&nbsp;was $11.6 million, up 73% from a year ago. And with a subscription and booking backlog of $682 million, up 80% from just a year ago, I think SoundHound will start turning a profit soon.



SOUN stock gets a &ldquo;B&rdquo; rating in the Portfolio Grader.



<h2>Kazia Therapeutics (KZIA)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/07/biotech1600-min-1-300x169.jpg" alt="an image of a microscope, NEXI stock"><div>Source: Shutterstock</div></div>Kazia Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/kzia-stock-quote/">KZIA</a>) is an Australian oncology company that&rsquo;s developing therapies for brain, liver and renal cancers.



The company&rsquo;s lead program is paxalisib, which is currently in Phase 3 trials as a treatment for glioblastoma, which is an aggressive form of brain cancer. Paxalisib is also in Phase 2 trials as a treatment for childhood brain cancers, brain metastases, and non-Hodgkin&rsquo;s lymphoma.



The stock had massive gains this month when it announced <a href="https://investorplace.com/2024/07/why-is-kazia-therapeutics-kzia-stock-up-300-today/">positive results</a> for paxalisib&rsquo;s glioblastoma trial. The company reported that patients who received paxalisib had a median overall survival period of 14.77 months, compared to 13.84 months for patients who did not receive the drug.



In a prespecified secondary analysis, the survival period for paxalisib patients was 15.54 months compared to 11.89 months for patients who did not take the drug.



Investing in biotech and pharma stocks can be very challenging because there&rsquo;s a lot of research &ndash; and a lot of expense &ndash; before a drug can even go to regulators for possible approval. But Kazia&rsquo;s work appears to be promising, and that&rsquo;s driving the momentum of KZIA stock right now.



Kazia stock is up 40% over the last month, and gets a &ldquo;B&rdquo; rating in the Portfolio Grader.



<h2>Koss (KOSS)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2024/07/koss1600-300x169.png" alt="Koss Porta Pro Wireless headphones on a round case like on your head on a white background with reflection"><div>Source: PhotOleh / Shutterstock.com</div></div>Koss (NASDAQ:<a href="https://investorplace.com/stock-quotes/koss-stock-quote/">KOSS</a>) is a manufacturer of headphones and accessories such as earbuds, electrostatic headphones and audio products for health care and education.



The company has been around for more than 60 years and came to renewed prominence in recent years as a popular meme stock. The meme factor makes Koss a volatile stock &ndash; shares jumped <a href="https://investorplace.com/2024/07/koss-stock-alert-koss-surges-90-on-renewed-meme-interest/">90% earlier this month</a> on speculative short-seller interest.



Earnings for the company&rsquo;s fiscal third quarter (ending March 31) showed weakening performance. Sales of $2.6 million was down from $3.3 million in the same quarter a year ago. Profits of $841,000 were down from $1.3 million on a year-over-year basis.



Koss is purely a meme stock play and should be treated with a lot of caution. If the stock jumps again &ndash; and odds are that it will &ndash; it would be wise to take profits at the peak.



KOSS stock is up 171% this year and gets a &ldquo;B&rdquo; rating in the Portfolio Grader.



<h2>VivoPower International (VVPR)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2023/05/electric-vehicle-ev-stocks-charging-black-neon-1600-300x169.jpg" alt="Electric car backlit by cyan blue neon light next to EV charger with cyan blue light and lightning bolt symbol, all against a black background. ev stocks to buy"><div>Source: shutterstock.com/JLStock</div></div>VivoPower International (NASDAQ:<a href="https://investorplace.com/stock-quotes/vvpr-stock-quote/">VVPR</a>) is an international battery technology and electric vehicle services company headquartered in the U.K. The company also operates in Australia, Canada, the Netherlands, the Philippines, the UAE and the U.S.



The company is preparing for a <a href="https://finance.yahoo.com/news/vivopower-announces-binding-heads-agreement-151900389.html">merger of its subsidiary</a>, Tembo E-LV, with Cactus Acquisition Corp. 1 Limited (NASDAQ:<a href="https://investorplace.com/stock-quotes/cctsw-stock-quote/">CCTSW</a>), a special purpose acquisition company in preparation for taking Tembo public. Tembo, which is an electric vehicle services company in the Netherlands. 



Following the merger, the new Tembo Group expects to be publicly traded on the Nasdaq exchange. The new company would have a valuation of $838 million, with VivoPower shareholders receiving 20% of the company.



Thus, VVPR stock is an interesting bet on EVs with heavy European exposure. VivoPower stock is up 37% this year and gets a &ldquo;B&rdquo; rating in the Portfolio Grader.



<h2>Soligenix (SNGX)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2024/07/sngx1600-300x169.png" alt="Soligenix is a leading biopharmaceutical firm developing drugs for rare diseases. It's renowned for solutions in oncology biodefense fields. SNGX stock"><div>Source: MacroEcon / Shutterstock.com</div></div>Soligenix (NASDAQ:<a href="https://investorplace.com/stock-quotes/sngx-stock-quote/">SNGX</a>) is a U.S. biopharmaceutical company that is working on a variety of products. It currently has several drug candidates in advanced stages of trials, including a treatment for early-stage cutaneous T-cell lymphoma in Phase 3 testing.



Soligenix has other Phase 2 tests underway for psoriasis, oral mucositis, and pediatric Crohn&rsquo;s disease.



But it&rsquo;s the early-stage cutaneous T-cell lymphoma trial that has investors excited. The stock jumped nearly 300% earlier this month &ndash; before giving some of those gains back &ndash; following a study testing HyBryte as a treatment). 



Six patients are enrolled in the yearlong study, with four of them completing at least 12 weeks of treatment. Of those, Soligenix says three patients already achieved treatment success, which is a 50% improvement in their cumulative mCAILS score compared to baseline. The fourth patient also saw improvement, the company said.



While this is a positive development, it&rsquo;s important to recognize that HyBryte is still a long way from making it to regulatory approval. But as a speculative play, SNGX stock has potential.



The stock is up 48% in the last month and has a &ldquo;B&rdquo; rating in the Portfolio Grader.



<h2>First Foundation (FFWM)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2021/05/piggy-bank-grad-300x169.jpg" alt="A pink piggy bank wearing a grad cap sits on a wooden table in front of a chalkboard."><div>Source: Shutterstock</div></div>First Foundation (NYSE:<a href="https://investorplace.com/stock-quotes/ffwm-stock-quote/">FFWM</a>) is a regional bank that&rsquo;s headquartered in Dallas, but has offices in California, Florida, Hawaii, Nevada and Texas.



The bank has $13.6 billion in assets as well as $10.1 billion of loans, deposits of $10.6 billion and stockholder equity of $929 million.



It also just completed an <a href="https://investor.ff-inc.com/news/news-details/2024/First-Foundation-Inc.-Closes-228-Million-Equity-Investment-Anchored-by-Fortress-Investment-Group-Canyon-Partners-Strategic-Value-Bank-Partners-and-North-Reef-Capital/default.aspx">investment deal</a> with several investment firms, including Fortress Investment Group, Canyon Partners, Strategic Value Bank Partners and North Reef Capital that injected $228 million into the company. First Foundation issued 11.3 million shares of stock valued at $4.10 each as part of the transaction.



The company is reporting second-quarter earnings on July 25, with <a href="https://investorplace.com/2024/07/why-is-first-foundation-ffwm-stock-down-27-today/">analysts expecting</a> flat adjusted earnings per share as well as revenue of $54.48 million. A year ago in the second quarter, FFWM saw $61.1 million in revenue and earnings of 7 cents per share.



Regional banking stocks have been challenging investments for the last few quarters, but FFWM appears to be on an upswing. The stock is up 25% in the last month and gets a &ldquo;B&rdquo; rating in the Portfolio Grader.



On the date of publication, neither Louis&nbsp;Navellier nor the InvestorPlace Research Staff member primarily responsible for this article held (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com <a href="https://url.us.m.mimecastprotect.com/s/AAadCPNlWWs3yKYns0yRM6?domain=investorplace.com/">Publishing Guidelines</a>.



On the date of publication, the responsible editor did not have (either directly or indirectly) and positions in the securities mentioned in this article.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>
The post <a href="https://investorplace.com/market360/2024/07/7-top-stocks-under-10-july-2024-edition/">7 Top Stocks Under $10: July 2024 Edition</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

7 Top Stocks Under $10: July 2024 Edition

Kazia Therapeutics files to sell $100M of American Depositary Shares

Kazia Therapeutics enters into licensing agreement with QIMR Berghofer

Kazia Therapeutics (KZIA) has released an update. Kazia Therapeutics has secured an exclusive worldwide license from QIMR Berghofer Medical Researc...

Kazia Therapeutics Advances Cancer Treatment Options

Kazia Therapeutics (KZIA) has released an update. Kazia Therapeutics presented promising data from a Phase 1 trial of EVT801, showing potential as ...

Kazia Therapeutics Reveals Hopeful Ovarian Cancer Study

ABBV

ABVE

CCTSW

CURLF

DBGI

FCEL

FFIE

FFWM

FORD

GILD

JOBY

KOSS

MAXN

MCAC

NUWE

PLUG

SNGX

SNOA

SOUN

VVPR

Press Releases

Kazia Therapeutics licenses paxalisib to Sovargen for intractable seizures in rare central nervous system diseases

KAZIA REPORTS SUCCESSFUL STAGE 1 COMPLETION OF THE EVT801 PHASE 1 CLINICAL TRIAL IN ADVANCED CANCER PATIENTS

Kazia Granted 180-Day Extension by Nasdaq to Meet the Minimum Bid Price Requirement

Small Cap

KAZIA ANNOUNCES UPCOMING DIPG DATA PRESENTATIONS AT ISPNO AND PUBLICATION IN EUROPEAN JOURNAL OF CANCER

Kazia Therapeutics Announces Phase II/III Clinical Trial Results for Paxalisib in Glioblastoma

Biotech Experiences Strong Open Following Major Announcement

Citius Pharmaceuticals (CTXR) Nears Key FDA Decisions and Launch Plans for 2024

Citius Pharmaceuticals (CTXR) Eyes Breakthrough with Late-Stage Drug Pipeline Poised for Regulatory Approval

KAZIA EXECUTES LICENSING AGREEMENT WITH QIMR BERGHOFER

Kazia Therapeutics Announces Presentation of EVT801 Clinical Data at 15th Biennial Ovarian Cancer Research Symposium

Top Stock Ideas Sent Daily — Join and Gain Your Edge

Top Stock Ideas Sent Daily — Join and Gain Your Edge

Comments

Kazia Therapeutics

Kazia Therapeutics (KZIA) Forecast

Kazia Therapeutics (NASDAQ:KZIA) Stock, Quote.Headers.trade-ideas